Form 8-K - Current report:
SEC Accession No. 0001628280-26-042176
Filing Date
2026-06-10
Accepted
2026-06-10 16:05:24
Documents
11
Period of Report
2026-06-09
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K bcax-20260609.htm   iXBRL 8-K 35708
  Complete submission text file 0001628280-26-042176.txt   158420

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcax-20260609.xsd EX-101.SCH 1779
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcax-20260609_lab.xml EX-101.LAB 23435
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcax-20260609_pre.xml EX-101.PRE 13579
14 EXTRACTED XBRL INSTANCE DOCUMENT bcax-20260609_htm.xml XML 2910
Mailing Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116
Business Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116 617-468-4219
Bicara Therapeutics Inc. (Filer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42271 | Film No.: 261079652
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)